步长制药(603858) - 2017 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders decreased by 10.20% to CNY 1.13 billion for the first nine months[6] - Basic earnings per share decreased by 19.40% to CNY 1.6575[7] - The weighted average return on equity decreased by 7.26 percentage points to 8.91%[7] - Total operating revenue for Q3 2017 was CNY 3,694,151,105.71, a decrease of 4.07% compared to CNY 3,851,494,836.24 in Q3 2016[29] - Net profit for Q3 2017 was CNY 452,399,595.87, down 30.67% from CNY 653,276,328.68 in Q3 2016[30] - Total profit for Q3 2017 was CNY 529,492,194.59, a decrease of 33.18% from CNY 792,986,144.47 in Q3 2016[30] - The net profit for the third quarter of 2017 was CNY 43,707,080.39, an increase from CNY 31,385,006.08 in the same period last year, representing a growth of approximately 39.5%[35] - The total operating income for the first nine months of 2017 reached CNY 11,329,731,429.05, compared to CNY 10,102,892,315.68 in the previous year, indicating a year-on-year increase of about 12.1%[37] Assets and Liabilities - Total assets decreased by 6.76% to CNY 17.41 billion compared to the end of the previous year[6] - Cash and cash equivalents decreased by 52.84% to ¥1,795,307,848.76 from ¥3,806,623,353.00, primarily due to payments for equity acquisitions[11] - Accounts receivable decreased by 88.33% to ¥129,595,492.77 from ¥1,110,925,808.21, attributed to bank acceptance bills and their maturity[11] - Non-current assets totaled CNY 11,471,164,191.03, an increase from CNY 10,256,125,089.52 year-on-year, reflecting a growth of approximately 11.8%[20] - Total liabilities decreased to CNY 4,722,044,494.52 from CNY 5,960,155,665.44, a decline of about 20.8%[21] - Current liabilities amounted to CNY 4,415,099,650.90, down from CNY 5,656,924,471.79, indicating a reduction of approximately 22%[20] - The company's equity attributable to shareholders increased to CNY 12,634,226,137.94 from CNY 12,606,015,914.99, a slight increase of approximately 0.2%[21] Cash Flow - Net cash flow from operating activities increased by 10.87% to CNY 1.66 billion for the first nine months[6] - Cash received from operating activities decreased by 48.52% to ¥121,310,270.67 from ¥235,642,971.29, mainly due to a reduction in government subsidies received[16] - The company reported a significant increase in cash received from borrowings, which rose by 192.09% to ¥1,900,000,000.00 from ¥650,490,000.00 during the reporting period[17] - Cash inflow from operating activities totaled $1,792,069,659.05, an increase of 13.5% compared to $1,578,549,098.81 in the same period last year[41] - Cash inflow from financing activities amounted to $1,600,000,000.00, up 220.0% from $500,000,000.00 in the same period last year[41] Expenses and Income - Financial expenses decreased by 81.96% to ¥34,393,014.64 from ¥190,643,741.68, mainly due to the recognition of deferred payment interest and exchange losses in the previous year[14] - Asset impairment losses decreased by 61.77% to ¥23,275,897.93 from ¥60,878,290.24, primarily due to a reduction in bad debt provisions for accounts receivable[14] - The company incurred financial expenses of CNY 4,383,175.64 in the third quarter, compared to CNY 60,824,532.09 in the same period last year, showing a decrease[35] - The investment income for the third quarter was CNY 26,479,275.94, a notable increase from CNY 1,937,106.40 in the same period last year[35] Shareholder Information - The total number of shareholders reached 50,939 by the end of the reporting period[8] - The largest shareholder, Bunch (Hong Kong) Holdings, holds 42.61% of the shares[9]